2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5869 Advancing multiple myeloma therapy with AZD4045 BCMA universal effector cells: A novel off‑the‑shelf cell therapy with potent pre-clinical efficacy engineered for scalability

Deepali Malhotra, PhD, Jessica Tong2, Ariel Raybuck3, Kelly McGlinchey4, Bhaumik Pandya5, Madison Temples6, Junchen Gu7, Emily Jennings8, Afua Akuffo9, Agnieszka Sadowska10, Giovanni Ciotta11, Jennifer Harbottle12, Lauren Zebertavage13, Lu Li14, Angelos Papadopoulos15, Muhammad Ekram16, Lisa Godfrey17, Michael Overstreet, PhD18, Gordon Moody19, Mark Cobbold, MD, PhD20
1 AstraZeneca, Gaithersburg, Maryland, United States
2 AstraZeneca, Gaithersburg, Maryland, United States
3 AstraZeneca, Gaithersburg, Maryland, United States
4 AstraZeneca, Gaithersburg, Maryland, United States
5 AstraZeneca, Gaithersburg, Maryland, United States
6 AstraZeneca, Gaithersburg, Maryland, United States
7 AstraZeneca, Waltham, Massachusetts, United States
8 AstraZeneca, Waltham, Massachusetts, United States
9 AstraZeneca, Gaithersburg, Maryland, United States
10 AstraZeneca, Gaithersburg, Maryland, United States
11 AstraZeneca, Cambridge, United Kingdom
12 AstraZeneca, Cambridge, United Kingdom
13 AstraZeneca, Gaithersburg, Maryland, United States
14 AstraZeneca, Cambridge, United Kingdom
15 AstraZeneca, Cambridge, United Kingdom
16 AstraZeneca, Waltham, Massachusetts, United States
17 AstraZeneca, Cambridge, United Kingdom
18 AstraZeneca, Gaithersburg, Maryland, United States
19 AstraZeneca, Gaithersburg, Maryland, United States
20 AstraZeneca, Gaithersburg, Maryland, United States

Autologous CAR‑T cell therapies have transformed the treatment landscape for multiple myeloma (MM), but the full impact of these advances is constrained by prolonged manufacturing times, high costs, product variability, and complex clinical and logistical infrastructure requirements. While allogeneic approaches offer the potential for off-the-shelf therapy, they typically require multiple genetic edits to reduce alloreactivity and necessitate prolonged ex vivo expansion to maximize numbers of clinical doses from each healthy donor. These requirements exacerbate limitations imposed by cellular senescence, create manufacturing bottlenecks and restrict patient access.

To enable a scalable, off‑the‑shelf solution, we developed AZD4045 BCMA Universal Effector Cells (UECs), engineered with a Renewably EXpandable (REX) phenotype via CRISPR/Cas9 ablation of CDKN2A, CDKN2B, and MTAP to limit induction replicative senescence during product manufacturing. When applied to healthy donor CD8+ T cells, REX-editing enabled ≥10^20‑fold expansion over extended culture (>100 days) while preserving cytotoxic function, CD8+ T cell attributes, and IL-2 dependence.

To minimize alloreactivity, B2M and TRAC were inactivated (95-100% KO by NGS), and CD38 was ablated (97-100% KO by NGS) to confer resistance to anti‑CD38 therapy. A second‑generation BCMA-targeting CAR was inserted into the B2M locus by homology-directed repair (99-100% CAR-detection by FACS). REX-editing enabled consistent cell manufacturing across donors and potentiated production of thousands of doses from a single healthy donor.

In vitro, AZD4045 demonstrated potent anti‑myeloma activity across MM cell lines (MM1S, RPMI‑8226, U266B1, NCIH929, and JJN3) comparable to that of (total T) CAR‑T controls while exhibiting improved cytokine secretion profiles (~80% reduction in IFN-γ and TNF-α), owing to its CD8+ T cell design and highlighting the potential to achieve efficacy while limiting cytokine release syndrome in patients.

In vivo, AZD4045 batches engineered from different healthy donors mediated robust, dose‑dependent control of MM1S tumors, reinforcing the ability of this platform to deliver scalable, consistent therapies. Further, combination of AZD4045 with IL‑2 support was well-tolerated, enabled deeper tumor clearance than by conventional CAR-Ts, and robustly limited extramedullary tumor outgrowth with as few as 100,000 BCMA UECs, suggesting the potential of AZD4045 to further improve patient outcomes.

Collectively, AZD4045 couples scalable, off‑the‑shelf manufacturing (thousands of doses per donor) with potent and reproducible anti‑myeloma activity, improved cytokine profiles relative to (total T) CAR‑T controls, and enhanced efficacy with IL‑2 support. These pre-clinical findings supported the initiation of a clinical study evaluating AZD4045 as a promising, accessible therapy for patients with relapsed/ refractory MM.

Deepali Malhotra, PhD: AstraZeneca - Current equity holder in publicly-traded company; AstraZeneca - Stock (publicly traded); AstraZeneca - Patents & Royalties; AstraZeneca - Current Employment